|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.880 USD | -5.06% |
|
+15.91% | +58.44% |
| Market Cap | 91.5M 79.78M 73.89M 69.17M 130M 8.63B 131M 877M 340M 4.25B 343M 336M 14.76B | P/E 2026 * |
-0.24x | P/E 2027 * | -0.24x |
|---|---|---|---|---|---|
| Enterprise Value | 46.31M 40.38M 37.4M 35.01M 65.66M 4.37B 66.05M 444M 172M 2.15B 174M 170M 7.47B | EV / Sales 2026 * |
13.5x | EV / Sales 2027 * | 31.6x |
| Free-Float |
-
| Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Limited
| 1 day | -5.06% | ||
| 1 week | +15.91% | ||
| Current month | +18.45% | ||
| 1 month | +14.29% | ||
| 3 months | +41.45% | ||
| 6 months | +57.93% | ||
| Current year | +58.44% |
| 1 week | 4.23 |  | 5.3 |
| 1 month | 3.88 | | 5.3 |
| Current year | 3.02 | | 5.3 |
| 1 year | 2.66 | | 7 |
| 3 years | 1 | | 7 |
| 5 years | 1 | | 27.5 |
| 10 years | 1 | | 66.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Niven
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.42M 2.99M 2.77M 2.59M 4.86M 323M 4.88M 32.81M 12.71M 159M 12.86M 12.58M 552M | 1.6M 1.4M 1.29M 1.21M 2.27M 151M 2.28M 15.33M 5.94M 74.33M 6.01M 5.88M 258M |
| Net income | -13.44M -11.72M -10.85M -10.16M -19.06M -1.27B -19.17M -129M -49.91M -624M -50.46M -49.38M -2.17B | -22.29M -19.43M -18M -16.85M -31.6M -2.1B -31.79M -214M -82.75M -1.04B -83.67M -81.87M -3.59B |
| Net Debt | -45.19M -39.4M -36.49M -34.16M -64.06M -4.26B -64.45M -433M -168M -2.1B -170M -166M -7.29B | -40.88M -35.64M -33.01M -30.9M -57.96M -3.86B -58.31M -392M -152M -1.9B -153M -150M -6.59B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/06/26 | 4.880 $ | -5.06% | 19,284 |
| 17/06/26 | 5.140 $ | +10.54% | 44,229 |
| 16/06/26 | 4.650 $ | +5.44% | 39,654 |
| 15/06/26 | 4.410 $ | +4.75% | 7,635 |
| 12/06/26 | 4.210 $ | +2.43% | 55,576 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
Select your edition
All financial news and data tailored to specific country editions
